Drug intelligence / Profile preview

DWC202001

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202001 is a small molecule drug candidate developed by Daewoong Pharmaceutical. It is currently in early clinical development, with its primary indication undisclosed. The compound has been studied in a Phase 1 clinical trial to evaluate drug-drug interactions when administered alone or in combination with other investigational agents (DWP16001 and DWC202002) in healthy male adults. The mechanism of action, specific molecular targets, and therapeutic area have not been publicly disclosed as of the latest available information[1][2][3].

Beyond the preview

Go deeper on DWC202001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202001.

Explore the full profile